Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Astellas: Overseas Sales Exceed 50% of Total Sales
November 19, 2007
- DSP: 4 Strategic Products Show Strong Sales
November 19, 2007
- Taisho: Stock Levels Normalized
November 19, 2007
- PMDA to Introduce Project Management System to Expedite NDA Review Process
November 19, 2007
- MTPC to Create Subsidiary to Promote Generic Drugs Business
November 19, 2007
- REGULATORY NEWS IN BRIEF
November 19, 2007
- Shionogi: Crestor Increases Profits with Royalty Income
November 19, 2007
- Prasugrel Reduces Risk of Serious CV Events by 19%: AHA
November 19, 2007
- Global Pharma Market to Grow 5-6% in 2008: IMS Health
November 19, 2007
- R&D NEWS IN BRIEF
November 19, 2007
- BUSINESS NEWS IN BRIEF
November 19, 2007
- Generics Dispensed for 1.4% of Prescriptions Permitting Substitution: Korosho Survey
November 19, 2007
- NEW PRODUCTS
November 19, 2007
- GENERICS NEWS IN BRIEF
November 19, 2007
- Council to Recommend Reductions in Medical Fees, NHI Drug Prices
November 19, 2007
- Korosho to Determine Information Needed When Selling OTC Drugs
November 19, 2007
- New IDF DM Management GL Stresses Importance of Postprandial Glucose
November 19, 2007
- Education on Vaccination for Uterine Cervical Cancer Needed
November 19, 2007
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
November 19, 2007
- Daiichi Sankyo to File Applications for Prasugrel in US, Europe
November 19, 2007
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…